Edition:
United States

Codexis Inc (CDXS.O)

CDXS.O on Nasdaq

4.60USD
24 Mar 2017
Change (% chg)

$0.10 (+2.22%)
Prev Close
$4.50
Open
$4.45
Day's High
$4.70
Day's Low
$4.40
Volume
145,447
Avg. Vol
114,332
52-wk High
$5.28
52-wk Low
$3.00

Latest Key Developments (Source: Significant Developments)

Codexis Q4 loss per share $0.13
Thursday, 9 Mar 2017 04:05pm EST 

Codexis Inc : Codexis reports 2016 fourth quarter and full year financial results . Q4 loss per share $0.13 . Q4 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S . Codexis Inc - total revenues for Q4 of 2016 were $10.0 million . Codexis Inc - research and development (research and development) expenses were $6.0 million for Q4 of 2016 compared with $5.2 million for q4 of 2015 . Codexis Inc- sees 2017 total revenues of $50 million to $53 million . Codexis Inc- sees 2017 product sales of $21 million to $23 million, an increase of 37% to 50% over 2016 . Codexis Inc- sees 2017 gross margin on product sales between 37% and 39% .Codexis inc- sees 2017 total operating expenses for research and development and sg&a to increase by 6% to 8%.  Full Article

Codexis to supply Tate & Lyle proprietary enzyme for food ingredient production
Tuesday, 6 Dec 2016 07:00am EST 

Codexis Inc :Codexis Inc - has entered into an exclusive agreement with Tate & Lyle to supply a proprietary enzyme for use in company's food ingredient production.  Full Article

Codexis reports Q2 adj. earnings per share $0.12
Tuesday, 9 Aug 2016 04:05pm EDT 

Codexis Inc : Codexis reports financial results for the second quarter of 2016 . Q2 earnings per share $0.05 . Sees FY 2016 revenue $46 million to $49 million . Q2 non-GAAP earnings per share $0.12 . Q2 earnings per share view $0.03 -- Thomson Reuters I/B/E/S .Q2 revenue $16 million versus I/B/E/S view $15.1 million.  Full Article

Codexis reports Q1 loss per share $0.17
Monday, 9 May 2016 04:05pm EDT 

Codexis Inc : Codexis reports financial results for the first quarter of 2016 . Q1 non-GAAP loss per share $0.11 . Q1 loss per share $0.17 . Q1 revenue $8.0 million versus I/B/E/S view $7.5 million .Q1 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S.  Full Article

Codexis Inc gives FY 2016 revenue guidance in line with analysts' estimates
Thursday, 3 Mar 2016 04:05pm EST 

Codexis Inc:Financial outlook for Fy 2016 is for another year of growth with revenues in the range of $46 million to $49 million.Expect gross margin for Fy 2016 to be between 80% and 85% of total revenues.FY 2016 REV VIEW $47.64 MLN -- THOMSON REUTERS I/B/E/S.  Full Article

Codexis signs multi-year extension of contract with merck to supply enzyme used in manufacture of sitagliptin
Friday, 18 Dec 2015 07:00am EST 

Codexis Inc:Announces the signing of an agreement extension with Merck Sharp & Dohme Corp to license and supply a proprietary enzyme used in the manufacturing process for sitagliptin.  Full Article

Codexis Inc reaffirms FY 2015 revenue guidance
Wednesday, 4 Nov 2015 04:05pm EST 

Codexis Inc:Affirms FY 2015 expectation for revenues to be in the range of $41 million to $44 million.FY 2015 revenue of $42 million - Thomson Reuters I/B/E/S.  Full Article

Codexis Inc raises FY 2015 revenue outlook
Tuesday, 11 Aug 2015 04:05pm EDT 

Codexis Inc:Expects FY 2015 total revenues to be between $41 and $44 million, this compares favorably with prior guidance of total revenues of $39 to $42 million.FY 2015 revenue of $41 million - Thomson Reuters I/B/E/S.  Full Article

Codexis entered into collaborative research and development agreement with Biopharmaceutical Co
Tuesday, 11 Aug 2015 07:00am EDT 

Codexis Inc:Has entered into collaborative research and development agreement with global biopharmaceutical company.Codexis will employ codeevolver to develop novel enzyme for use in its partner's preclinical therapeutic development program.Says under terms of agreement, Codexis has received $1 mln upfront payment.Says Codexis could also receive additional payments.  Full Article

Codexis, Inc enters into agreement with Merck, Sharp & Dohme Corp - Form 8-K
Monday, 3 Aug 2015 04:27pm EDT 

Codexis, Inc:Entered into a platform technology transfer and license agreement with Merck, Sharp & Dohme Corp.Codexis granted to Merck license to use Codexis’ CodeEvolver Platform Technology to research, develop and manufacture novel enzymes for use by Merck for internal research programs.Merck will pay Codexis up to $18 million over the next 15 to 24 months.  Full Article

More From Around the Web

BRIEF-Codexis Q4 loss per share $0.13

* Codexis reports 2016 fourth quarter and full year financial results